

---

**THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION**

---

If you are in any doubt about the contents of this circular, you should consult your stockbroker or other licensed securities dealer, bank manager, solicitor, accountant or other professional adviser immediately.

If you have sold or transferred your shares in Shenzhen Hepalink Pharmaceutical Group Co., Ltd., you should nevertheless immediately inform the person to whom you sold or transferred the shares of the contents of this circular, so that they can contact their own stockbroker or other licensed securities dealer, bank manager, solicitor, accountant or other professional adviser immediately.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

---



( )  
(A joint stock company incorporated in the People's Republic of China with limited liability)  
(Stock code: 9989)

**2022 WORK REPORT OF THE BOARD OF DIRECTORS  
2022 WORK REPORT OF THE SUPERVISORY COMMITTEE  
2022 ANNUAL REPORT AND ITS SUMMARY,  
H SHARES RESULTS ANNOUNCEMENT,  
H SHARES 2022 ANNUAL REPORT, 2022 CORPORATE GOVERNANCE REPORT AND  
2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT  
2022 FINAL FINANCIAL REPORT  
2022 PROFIT DISTRIBUTION PROPOSAL  
RE-APPOINTMENT OF AUDITORS OF THE COMPANY  
ELECTION OF THE SIXTH SESSION OF THE BOARD  
REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF  
THE SIXTH SESSION OF THE BOARD  
ELECTION OF THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE  
PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND CASH FLOW MANAGEMENT  
USING INTERNAL FUNDS  
APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO CERTAIN BANKS FOR 2023  
AMENDMENT OF ARTICLES OF ASSOCIATION  
AND  
NOTICE OF THE 2022 ANNUAL GENERAL MEETING**

---

A meeting of the Board of Directors of the Company will be held on 22, 2023 (Wednesday) at 2:30 p.m. (China Standard Time) at the Company's Head Office, Room 3031, 30th Floor, Hepalink Building, No. 11, Jiefang Avenue, Shenzhen, P.R. China (AGM).

A meeting of the Supervisory Committee of the Company will be held on 22, 2023 (Wednesday) at 2:30 p.m. (China Standard Time) at the Company's Head Office, Room 3031, 30th Floor, Hepalink Building, No. 11, Jiefang Avenue, Shenzhen, P.R. China.

A meeting of the 2022 Annual General Meeting of the Company will be held on 24, 2023 (Friday) at 10:00 a.m. (China Standard Time) at the Company's Head Office, Room 3031, 30th Floor, Hepalink Building, No. 11, Jiefang Avenue, Shenzhen, P.R. China.

The Board of Directors of the Company has resolved to pay a final dividend of RMB 0.17 per share for the year ended 31, 2022. The dividend will be paid on 16, 2023 (Friday) at 10:00 a.m. (China Standard Time) at the Company's Head Office, Room 3031, 30th Floor, Hepalink Building, No. 11, Jiefang Avenue, Shenzhen, P.R. China. A meeting of the Board of Directors of the Company will be held on 24, 2023 (Friday) at 10:00 a.m. (China Standard Time) at the Company's Head Office, Room 3031, 30th Floor, Hepalink Building, No. 11, Jiefang Avenue, Shenzhen, P.R. China.

---

# CONTENTS

---

	<i>P.</i>
<b>DEFINITIONS</b> .....	1
<b>LETTER FROM THE BOARD</b> .....	3
1. ....	4
2. ....	4
2022 .....	4
2022 .....	5
2022 Annual General Meeting, 2022 Annual General Meeting, 2022 Annual General Meeting, 2022 Annual General Meeting .....	5
2022 .....	5
2022 .....	5
.....	6
.....	6
.....	7
.....	7
.....	9
Annual General Meeting 2023 .....	9
Annual General Meeting, Annual General Meeting .....	9
3. Annual General Meeting .....	9
4. <input checked="" type="checkbox"/> .....	10
5. ....	11
<b>APPENDIX I – PROFILES OF THE PROPOSED SIXTH SESSION OF THE BOARD</b> ...	12
<b>APPENDIX II – AMENDMENT OF ARTICLES OF ASSOCIATION</b> .....	18
<b>NOTICE OF THE 2022 ANNUAL GENERAL MEETING</b> .....	20
<i>Notes</i> .....	20

---

## DEFINITIONS

---

*L* is a linear operator on a vector space  $V$  over a field  $F$ . Let  $\alpha \in F$ . Define  $L_\alpha$  by  $L_\alpha(v) = \alpha L(v)$  for all  $v \in V$ .

A . . .



---

LETTER FROM THE BOARD

---



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**( 深圳市海普瑞藥業集團股份有限公司 )**  
*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9989)**

English: (C... B...)  
(D... G... M...)  
(G... M...)

P... C:  
21

Chinese: D...  
...

P...  
H... K...  
4724, 471  
30  
K...

April 20, 2023

**2022 WORK REPORT OF THE BOARD OF DIRECTORS**  
**2022 WORK REPORT OF THE SUPERVISORY COMMITTEE**  
**2022 ANNUAL REPORT AND ITS SUMMARY,**  
**H SHARES RESULTS ANNOUNCEMENT,**  
**H SHARES 2022 ANNUAL REPORT,**  
**2022 CORPORATE GOVERNANCE REPORT AND**  
**2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT**  
**2022 FINAL FINANCIAL REPORT**  
**2022 PROFIT DISTRIBUTION PROPOSAL**  
**RE-APPOINTMENT OF AUDITORS OF THE COMPANY**  
**ELECTION OF THE SIXTH SESSION OF THE BOARD**  
**REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF**  
**THE SIXTH SESSION OF THE BOARD**  
**ELECTION OF THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE**  
**PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND**  
**CASH FLOW MANAGEMENT**  
**USING INTERNAL FUNDS**  
**APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO**  
**CERTAIN BANKS FOR 2023**  
**AMENDMENT OF ARTICLES OF ASSOCIATION**

---

# LETTER FROM THE BOARD

---

## 1. INTRODUCTION

The Board of Directors (the "Board") of the Company is pleased to announce the results of the 2022 Annual Meeting of Shareholders (the "Annual Meeting") held on November 10, 2022. The following information is provided for your information:

A. The Board has approved the following resolutions:

- (1) To approve the 2022 Annual Report of the Board of Directors.
- (2) To approve the 2022 Annual Report of the Management.
- (3) To approve the 2022 Annual Report of the Supervisors, the 2022 Annual Report of the Auditors, and the 2022 Annual Report of the Company.
- (4) To approve the 2022 Annual Report of the Company.
- (5) To approve the 2022 Annual Report of the Company.
- (6) To approve the 2022 Annual Report of the Company.
- (7) To approve the 2022 Annual Report of the Company.
- (8) To approve the 2022 Annual Report of the Company.
- (9) To approve the 2022 Annual Report of the Company.

A. The Board has approved the following resolutions:

- (10) To approve the 2022 Annual Report of the Board of Directors.
- (11) To approve the 2022 Annual Report of the Management.
- (12) To approve the 2022 Annual Report of the Supervisors, the 2022 Annual Report of the Auditors, and the 2022 Annual Report of the Company.

## 2. MATTERS TO BE CONSIDERED AT THE ANNUAL GENERAL MEETING

### i. 2022 Work Report of the Board of Directors

The Board of Directors has reviewed the 2022 Annual Report of the Board of Directors and the 2022 Annual Report of the Management, and has approved the 2022 Annual Report of the Board of Directors and the 2022 Annual Report of the Management.

The Board of Directors has reviewed the 2022 Annual Report of the Supervisors, the 2022 Annual Report of the Auditors, and the 2022 Annual Report of the Company, and has approved the 2022 Annual Report of the Supervisors, the 2022 Annual Report of the Auditors, and the 2022 Annual Report of the Company.

---

## LETTER FROM THE BOARD

---

### ii. 2022 Work Report of the Supervisory Committee

The Supervisory Committee has reviewed the 2022 Work Report of the Supervisory Committee, which was approved by the Board of Supervisors on December 29, 2023. The Board of Supervisors has also reviewed the 2022 Work Report of the Supervisory Committee, which was approved by the Board of Supervisors on December 29, 2023.

### iii. 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report

The Board of Supervisors has reviewed the 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report, which were approved by the Board of Supervisors on December 29, 2023. The Board of Supervisors has also reviewed the 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report, which were approved by the Board of Supervisors on December 29, 2023.

### iv. 2022 Final Financial Report

The Board of Supervisors has reviewed the 2022 Final Financial Report, which was approved by the Board of Supervisors on December 29, 2023. The Board of Supervisors has also reviewed the 2022 Final Financial Report, which was approved by the Board of Supervisors on December 29, 2023.

### v. 2022 Profit Distribution Proposal

The Board of Supervisors has reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Supervisors on December 31, 2022 (the "Final Dividend"). The Board of Supervisors has also reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Supervisors on December 31, 2022.

The Board of Supervisors has reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Supervisors on December 31, 2022. The Board of Supervisors has also reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Supervisors on December 31, 2022.







---

## LETTER FROM THE BOARD

---

董事鄭澤輝先生(鄭澤輝), 45歲, 現年53, 於2006年加入本公司。彼於1992年畢業於香港中文大學, 獲文學士學位。彼於2011年獲委任為本公司董事。

董事唐海均先生(唐海均), 44歲, 現年44, 於2001年加入本公司。彼於2007年獲委任為本公司董事。彼於2014年獲委任為本公司董事。

董事A先生, 現年A, 於A年加入本公司。彼於A年獲委任為本公司董事。彼於A年獲委任為本公司董事。

董事B先生, 現年B, 於B年加入本公司。彼於B年獲委任為本公司董事。彼於B年獲委任為本公司董事。

董事C先生, 現年C, 於C年加入本公司。彼於C年獲委任為本公司董事。彼於C年獲委任為本公司董事。

董事D先生, 現年D, 於D年加入本公司。彼於D年獲委任為本公司董事。彼於D年獲委任為本公司董事。

董事E先生, 現年E, 於E年加入本公司。彼於E年獲委任為本公司董事。彼於E年獲委任為本公司董事。

---

## LETTER FROM THE BOARD

---

x. **Purchase of Wealth Management Products and Cash Flow Management Using Internal Funds**

The Board has approved the purchase of wealth management products and cash flow management using internal funds for the period from January 1, 2023 to December 31, 2023.

The Board has approved the purchase of wealth management products and cash flow management using internal funds for the period from January 1, 2023 to December 31, 2023.

xi. **Application for Credit Line and Providing Guarantee to Certain Banks for 2023**

The Board has approved the application for credit line and providing guarantee to certain banks for the period from January 1, 2023 to December 31, 2023.

The Board has approved the application for credit line and providing guarantee to certain banks for the period from January 1, 2023 to December 31, 2023.

xii. **Amendment of Articles of Association**

The Board has approved the amendment of Articles of Association for the period from January 1, 2023 to December 31, 2023.

The Board has approved the amendment of Articles of Association for the period from January 1, 2023 to December 31, 2023.

3. **ANNUAL GENERAL MEETING AND CLOSURE OF REGISTER OF MEMBERS OF H SHARES**

The Board has approved the annual general meeting and closure of register of members of H shares for the period from January 1, 2023 to December 31, 2023.

---

## LETTER FROM THE BOARD

---

... 17/ ... 16 ... 24 ...  
A

... 17, 2023 ... 22, 2023 (...  
...), ... A ...  
... 17/ ... 16 ... 4:30 ...  
16, 2023. ...  
22, 2023 ... A

... 29, 2023 ... 31,  
2023, ...  
... 17/ ...  
... 16 ... 4:30 ... 25, 2023.  
... 31, 2023  
... 2022  
A

#### 4. VOTING BY POLL

... 13.39(4) ...  
A ... A

A ... A ...  
... A ...  
... ( ) ...  
... ( ) ... A ... 20  
... 24 ...

---

## LETTER FROM THE BOARD

---

### 5. RECOMMENDATION

1. The Board of Directors of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company") has reviewed the financial statements of the Company for the year ended December 31, 2022, and the Board of Directors has approved the financial statements of the Company for the year ended December 31, 2022.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Li Li

Chairman

A ... A ...

**Non-independent Directors****(i) Mr. Li Li**

(李鋌), 59, ... 28 ... A ... 2012

(ii) Ms. Li Tan

(李坦), 58, ... 28, ... A ... 1998. ... 2007; ... 2007; ... ( ) ... 2014; ... 2010; ... A ... 2013; ... A ... 2015; ... A ... 2016.

( ) ... 1987 ... 2005.

A 922,391,179 A , 73.96% A A ( ) 408,041,280 A ( 99.00% 1.00% ); ( ) 474,029,899 A ( 99.00% 1.00% ); ( ) 40,320,000 A ( ) .

(iii) Mr. Shan Yu

(單宇), 62, 28

1998. 2000; 2007; 2009; 2009; 2010; 2013; A 2014.

1982 2005.

A 99% 46,425,600 A 38.88% 15,118,035 A 52,302,892 A 3.56%

(iv) Mr. Zhang Ping

(張平), 58, 1992 1998,

30. 2021. A 2022. A 2002. 2021

1988. 2002.

A A A A





A

(vi) Mr. Huang Peng

(黃鵬), 74, 1949, 2003.  
 1995  
 1985.  
 1988,  
 (新時代企業家研究院)  
 A A ( : 601890), ( : 301180), ( : 300819) & ( : 603828).

A

A A  
 A A

A

(vii) Mr. Yi Ming

(易銘), 46, 1977, 2002 A 2014.  
 ( ) A  
 2003 2012. (A) A  
 2013 2018. A A  
 2018.

A

A A  
 A A

A





Existing Provisions of the Articles of Association	Proposed Amendments to the Articles of Association
<p>A</p> <p>( )</p> <p>E</p> <p>A</p> <p>A</p>	<p>A</p> <p>( )</p> <p>E</p> <p>A</p> <p>A</p>
<p><b>Article 150</b></p>	<p><b>Article 150</b></p>
<p><b>Article 156</b></p>	<p><b>Article 156</b></p>
<p><b>Article 158</b></p> <p>/</p> <p>/</p>	<p><b>Article 158</b></p> <p>/</p> <p>/</p>



---

## NOTICE OF THE 2022 ANNUAL GENERAL MEETING

---

### ORDINARY RESOLUTION

8. To approve the financial statements for the year ended 31 December 2021 and the directors' report and the auditors' report thereon;

### SPECIAL RESOLUTION

9. To approve the proposed amendments to the Memorandum and Articles of Association of the Company, as set out in the Special Resolution Notice, and to authorize the directors to execute all such documents and to do all such things as may be necessary to give effect to the amendments.

### ORDINARY RESOLUTIONS

10. To approve the proposed amendments to the Memorandum and Articles of Association of the Company, as set out in the Ordinary Resolution Notice, and to authorize the directors to execute all such documents and to do all such things as may be necessary to give effect to the amendments;
11. To approve the proposed amendments to the Memorandum and Articles of Association of the Company, as set out in the Ordinary Resolution Notice, and to authorize the directors to execute all such documents and to do all such things as may be necessary to give effect to the amendments:
- 11.01 To approve the proposed amendments to the Memorandum and Articles of Association of the Company, as set out in the Ordinary Resolution Notice, and to authorize the directors to execute all such documents and to do all such things as may be necessary to give effect to the amendments;
  - 11.02 To approve the proposed amendments to the Memorandum and Articles of Association of the Company, as set out in the Ordinary Resolution Notice, and to authorize the directors to execute all such documents and to do all such things as may be necessary to give effect to the amendments;
  - 11.03 To approve the proposed amendments to the Memorandum and Articles of Association of the Company, as set out in the Ordinary Resolution Notice, and to authorize the directors to execute all such documents and to do all such things as may be necessary to give effect to the amendments;
  - 11.04 To approve the proposed amendments to the Memorandum and Articles of Association of the Company, as set out in the Ordinary Resolution Notice, and to authorize the directors to execute all such documents and to do all such things as may be necessary to give effect to the amendments;

---

## NOTICE OF THE 2022 ANNUAL GENERAL MEETING

---

12. 审议《关于聘任2022年度高级管理人员的议案》；
- 12.01 审议《关于聘任2022年度高级管理人员的议案》；
- 12.02 审议《关于聘任2022年度高级管理人员的议案》；
- 12.03 审议《关于聘任2022年度高级管理人员的议案》；
13. 审议《关于聘任2022年度高级管理人员的议案》；
- 13.01 审议《关于聘任2022年度高级管理人员的议案》；
- 13.02 审议《关于聘任2022年度高级管理人员的议案》；

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Li Li

Chairman

2023年1月20日





---

## NOTICE OF THE 2022 ANNUAL GENERAL MEETING

---

- (iii) *[Faint, illegible text]*

9. *[Faint, illegible text]*